Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

This type affects 1 in 20 people with lymphoma and is more common in older adults and men. It forms in your spleen, lymph nodes, or bone marrow. Mantle cell lymphoma grows slowly but can be hard ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Adaptive Biotechnologies (ADPT) announced that Palmetto GBA, a Medicare Administrative Contractor, MAC, that assesses diagnostic technologies ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a ...